EGFR and non-small cell lung carcinoma: In total, baseline positron emission tomography–computed tomography (PET-CT) was performed for 488 patients (67.5%), and brain magnetic resonance imaging (MRI) was performed for 356 patients (35.4%), with no significant difference between EGFR-positive NSCLC and wildtype EGFR NSCLC groups.